Testoderm TTS CIII

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved December 1997

Specific Treatments:

testosterone deficiency

Therapeutic Areas

General Information

Testoderm TTS CIII has been approved for men with testosterone deficiency. It is a transdermal patch that delivers a 5-mg dose of testosterone during a 24-hour period.

Clinical Results

Clinical Results: Clinical trials showed that application of the Testoderm patch maintained normal serum testosterone levels, with delivery comparable to the normal circadian pattern of testosterone secretion.